Speaker Profile

Co-founder and Chief Scientific Officer, Microbiome Labs

Biography
Kiran Krishnan is a Research Microbiologist and has been involved in the dietary supplement and nutrition market for the past 17 years. He comes from a strict research background having spent several years with hands-on R&D in the fields of molecular medicine and microbiology at the University of Iowa. He left University research to take a position as the U.S. Business Development and Product Development lead for Amano Enzyme, USA. Amano is one of the world’s largest suppliers of therapeutic enzymes used in the dietary supplement and pharmaceutical industries in North America. Kiran also established a Clinical Research Organization where he designed and conducted dozens of human clinical trials in human nutrition. Kiran is also a co-founder and partner in Nu Science Trading, LLC.; a nutritional technology development, research and marketing company in the U.S. Dietary Supplement and Medical Food markets. Most recently, Kiran is acting as the Chief Scientific Officer at Physician’s Exclusive, LLC. and Microbiome Labs. He has developed over 50 private label nutritional products for small to large brands in the global market. He is a frequent lecturer on the Human Microbiome at Medical and Nutrition Conferences. He conducts the popular monthly Microbiome Series Webinars through the Rebel Health Tribe Group practitioner training program, is an expert guest on National Radio and Satellite radio and has been a guest speaker on several Health Summits as a microbiome expert. He is currently involved in 9 novel human clinical trials on probiotics and the human microbiome. Kiran is also on the Scientific Advisory Board for 5 other companies in the industry. Kiran offers his extensive knowledge and practical application of the latest science on the human microbiome as it relates to health and wellness.


 Session Abstract – PMWC 2022 Silicon Valley


Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.

Sessions:

Microbiome and Cancer
Jennifer Wargo, MD Anderon
Sandrine Miller-Montgomery, UCSD

The Gut/Brain Microbiome
Mary Conrad, Axial Biotherapeutics
Chris Reyes, Bloom Science
Rosa Krajmalnik-Brown, Arizona State University

The Role of the Human Gut Microbiome on Various Diseases
Colleen Cutcliffe, Pendulum Therapeutics
Tor Savidge, Baylor College of Medicine
Nikole Kimes, Siolta Therapeutics

Pharma Drug Development
Karim Dabbagh, Second Genome
Ethan Grant, Gilead

Direct-To-Consumer Testing/Technologies
Kiran Krishnan, Microbiome Labs
Nathan Price, Onegevity

Regulatory Perspective
Scott Jackson, NIST

Investment Perspective